Outlook Therapeutics

Outlook Therapeutics(OTLK)

ISELIN, NJ
Biotechnology
WebsiteLinkedInCareers Page

Focus: Biosimilars

Outlook Therapeutics is a life sciences company focused on Biosimilars.

OphthalmologyUnknown
Funding Stage
PUBLIC
Open Jobs
1

Pipeline & Clinical Trials

Phase 3
Clinical Trials (1)
NCT05112861A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Phase 3
Phase 3
Clinical Trials (1)
NCT06190093A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Phase 3
Clinical Trials (1)
NCT03834753A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Phase 3
Clinical Trials (1)
NCT03844074A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Phase 3
Phase 3
Clinical Trials (1)
NCT04516278A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Phase 3

Open Jobs (1)

Head of Finance, Europe

Unknown
Unknown
3w ago
Interview Prep Quick Facts
Founded: 2018
Portfolio: 5 clinical trials
SEC Filings: 2 available
Open Roles: 1 active job

Financials (FY2025)

Revenue
$1M
R&D Spend
$42M(2955%)58%
Net Income
-$75M
Cash
$15M
Source: SEC 10-K Filing